Back to Search Start Over

Tracking the progressive spread of the SARS-CoV-2 Omicron variant in Italy, December 2021 to January 2022

Authors :
Stefanelli, Paola
Trentini, Filippo
Petrone, Daniele
Mammone, Alessia
Ambrosio, Luigina
Manica, Mattia
Guzzetta, Giorgio
D'Andrea, Valeria
Marziano, Valentina
Zardini, Agnese
Molina Grane', Carla
Ajelli, Marco
Di Martino, Angela
Riccardo, Flavia
Bella, Antonino
Sane Schepisi, Monica
Maraglino, Francesco
Poletti, Piero
Palamara, Anna Teresa
Brusaferro, Silvio
Rezza, Giovanni
Pezzotti, Patrizio
Merler, Stefano
Mencacci, A
Camilloni, B
Stefanelli P, Trentini F, Petrone D, Mammone A, Ambrosio L, Manica M, Guzzetta G, d'Andrea V, Marziano V, Zardini A, Molina Grane' C, Ajelli M, Di Martino A, Riccardo F, Bella A, Sane Schepisi M, Maraglino F, Poletti P, Palamara AT, Brusaferro S, Rezza G, Pezzotti P, Merler S, Tramuto F
Source :
Eurosurveillance. 27
Publication Year :
2022
Publisher :
European Centre for Disease Control and Prevention (ECDC), 2022.

Abstract

Background The SARS-CoV-2 variant of concern Omicron was first detected in Italy in November 2021. Aim To comprehensively describe Omicron spread in Italy in the 2 subsequent months and its impact on the overall SARS-CoV-2 circulation at population level. Methods We analyse data from four genomic surveys conducted across the country between December 2021 and January 2022. Combining genomic sequencing results with epidemiological records collated by the National Integrated Surveillance System, the Omicron reproductive number and exponential growth rate are estimated, as well as SARS-CoV-2 transmissibility. Results Omicron became dominant in Italy less than 1 month after its first detection, representing on 3 January 76.9–80.2% of notified SARS-CoV-2 infections, with a doubling time of 2.7–3.3 days. As of 17 January 2022, Delta variant represented Conclusion Estimates suggest a marked growth advantage of Omicron compared with Delta variant, but lower disease severity at population level possibly due to residual immunity against severe outcomes acquired from vaccination and prior infection.

Details

ISSN :
15607917
Volume :
27
Database :
OpenAIRE
Journal :
Eurosurveillance
Accession number :
edsair.doi.dedup.....b5101cb186e876aeecc566cd38be0c5c